SAGE
SAGE Therapeutics Inc
Price:  
9.13 
USD
Volume:  
1,623,224.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

SAGE EV/EBITDA

-1493.6%
Upside

As of 2025-07-19, the EV/EBITDA ratio of SAGE Therapeutics Inc (SAGE) is -1.47. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SAGE's latest enterprise value is 526.50 mil USD. SAGE's TTM EBITDA according to its financial statements is -358.92 mil USD. Dividing these 2 quantities gives us the above SAGE EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 12.4x - 12.8x 12.6x
Forward P/E multiples 20.7x - 43.4x 32.0x
Fair Price (117.92) - (72.64) (127.24)
Upside -1391.6% - -895.7% -1493.6%
9.13 USD
Stock Price
(127.24) USD
Fair Price

SAGE EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2025-07-16 -1.47
2025-07-15 -1.47
2025-07-14 -1.47
2025-07-11 -1.49
2025-07-10 -1.48
2025-07-09 -1.48
2025-07-08 -1.47
2025-07-07 -1.47
2025-07-03 -1.48
2025-07-02 -1.46
2025-07-01 -1.46
2025-06-30 -1.47
2025-06-27 -1.47
2025-06-26 -1.49
2025-06-25 -1.49
2025-06-24 -1.48
2025-06-23 -1.50
2025-06-20 -1.50
2025-06-18 -1.47
2025-06-17 -1.47
2025-06-16 -1.46
2025-06-13 -1.04
2025-06-12 -1.03
2025-06-11 -1.06
2025-06-10 -1.09
2025-06-09 -1.06
2025-06-06 -1.07
2025-06-05 -1.06
2025-06-04 -1.02
2025-06-03 -1.01
2025-06-02 -1.03
2025-05-30 -1.00
2025-05-29 -1.01
2025-05-28 -1.00
2025-05-27 -1.01
2025-05-23 -1.01
2025-05-22 -1.03
2025-05-21 -1.06
2025-05-20 -1.12
2025-05-19 -1.11
2025-05-16 -1.08
2025-05-15 -1.03
2025-05-14 -0.99
2025-05-13 -1.03
2025-05-12 -1.05
2025-05-09 -1.02
2025-05-08 -1.04
2025-05-07 -1.06
2025-05-06 -1.07
2025-05-05 -1.12